Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Determining Biomarkers of Efficacy in DC Reprogramming Therapy
| Reference number | 2024-00579 |
| Coordinator | Asgard Therapeutics AB |
| Funding from Vinnova | SEK 0 |
| Project duration | April 2024 - April 2024 |
| Status | Completed |
| Venture | MSCA Employment |
| Call | Attract, integrate and retain international excellence by 2024 |
Last updated 29 April 2024
Reference number 2024-00579
